Glenmark Pharmaceuticals said that it has acquired an exclusive license to market a generic tiotropium bromide dry powder inhaler in Western Europe. The DPI, a generic version of Boehringer Ingelheim’s Spiriva Handihaler for the treatment of COPD, is the second inhaler Glenmark has licensed for the European market.
In 2015, Glenmark announced that it had entered into a deal with Celon to market a fluticasone/salmeterol DPI in 15 European countries. That inhaler was approved for the treatment of asthma and COPD through the decentralized procedure in the Nordic countries in late 2017.
Glenmark Executive VP and Business Head of Europe and Latin America Achin Gupta commented, “Respiratory is a core area of focus for Glenmark and this deal shows our commitment to increase product offerings within this segment. There is significant opportunity in the inhalers market and we believe that this deal will give further impetus to Glenmark’s growth in Europe.”
Read the Glenmark Pharmaceuticals press release.
